NASDAQ:NVCR

NovoCure - NVCR News Today

$57.17

+0.36 (+0.63%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $56.06
▼
$57.64
50-Day Range: $56.44
▼
$95.09
52-Week Range: $56.06
▼
$120.03

Volume: 561,258 shs
Average Volume: 1.09 million shs
Market Capitalization: $6.03 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $87.33

Institutional Ownership

Get NovoCure News Delivered to You Automatically

NVCR Media Mentions By Week

NVCR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NVCR
News Sentiment
▼
0.18

0.52
▲
Average
Medical
News Sentiment

NVCR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NVCR Articles
This Week
▼
5

3
▲
NVCR Articles
Average Week

Source

Source	Headline
	Armstrong Advisory Group Inc. Purchases New Shares in NovoCure Limited (NASDAQ:NVCR) marketbeat.com - March 24 at 6:23 AM
	NovoCure Limited (NASDAQ:NVCR) Shares Sold by Peregrine Capital Management LLC marketbeat.com - March 20 at 5:47 AM
	JPMorgan Chase & Co. Reaffirms "Underweight" Rating for NovoCure (NASDAQ:NVCR) americanbankingnews.com - March 20 at 3:36 AM
	Institutional investors may adopt severe steps after NovoCure Limited's (NASDAQ:NVCR) latest 7.3% drop adds to a year losses finance.yahoo.com - March 16 at 3:41 PM
	Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France finance.yahoo.com - March 1 at 12:07 PM
	NovoCure Full Year 2022 Earnings: US$0.88 loss per share (vs US$0.56 loss in FY 2021) finance.yahoo.com - February 24 at 7:39 AM
	NovoCure Full Year 2022 Earnings: US$0.88 loss per share (vs US$0.56 loss in FY 2021) finance.yahoo.com - February 24 at 7:39 AM
	Why NovoCure Stock Is Falling Today finance.yahoo.com - February 23 at 4:37 PM
	Should You Investigate NovoCure Limited (NASDAQ:NVCR) At US$87.50? finance.yahoo.com - February 10 at 5:58 AM
	Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes finance.yahoo.com - January 19 at 3:10 PM
	Novocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Grace finance.yahoo.com - January 17 at 1:29 PM
	Why Novocure Stock Is Flying High finance.yahoo.com - January 6 at 8:16 AM
	Novocure Skyrockets 69% After Pulling Off A Once-In-Six-Years Feat finance.yahoo.com - January 5 at 7:54 PM
	Why Novocure Stock Is Skyrocketing Today finance.yahoo.com - January 5 at 2:49 PM
	Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference finance.yahoo.com - December 27 at 8:32 AM
	Is NovoCure Limited (NASDAQ:NVCR) Worth US$74.7 Based On Its Intrinsic Value? finance.yahoo.com - November 30 at 11:49 AM
	Novocure Stock: Bull vs. Bear finance.yahoo.com - November 26 at 6:12 AM
	Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada finance.yahoo.com - November 15 at 9:39 AM
	Novocure Secures CE Mark for New Array finance.yahoo.com - November 11 at 1:02 PM
	2 Potentially Explosive Stocks to Buy in November finance.yahoo.com - November 8 at 1:50 PM
	NovoCure's Return On Capital Employed Insights msn.com - November 4 at 1:37 PM
	NovoCure (NVCR) Reports Q3 Loss, Lags Revenue Estimates finance.yahoo.com - October 27 at 6:06 PM
	Novocure (NVCR) Q3 2022 Earnings Call Transcript finance.yahoo.com - October 27 at 6:06 PM
	NovoCure downgraded at Piper Sandler despite positive Phase 3 readout ahead seekingalpha.com - October 25 at 1:10 PM
	Why Novocure Stock Is Sinking Today finance.yahoo.com - October 24 at 9:12 PM
	NovoCure (NASDAQ:NVCR) shareholders have earned a 30% CAGR over the last five years finance.yahoo.com - October 23 at 7:43 PM
	3 Unstoppable Stocks You Can Buy Now for Less Than $100 - Nasdaq nasdaq.com - October 13 at 10:57 AM
	The Clock Is Ticking to Buy This Game-Changing Stock at a Discount - Nasdaq nasdaq.com - October 6 at 10:17 AM
	The Clock Is Ticking to Buy This Game-Changing Stock at a Discount finance.yahoo.com - October 6 at 10:17 AM
	Novocure to Report Third Quarter 2022 Financial Results finance.yahoo.com - October 3 at 8:15 AM
	NovoCure: See Past Market Myopia And Buy The Dip (NASDAQ:NVCR) - Seeking Alpha seekingalpha.com - September 27 at 8:40 PM
	NVCR Makes Notable Cross Below Critical Moving Average - Nasdaq nasdaq.com - September 23 at 9:45 AM
	NovoCure Whale Trades For September 21 - NovoCure (NASDAQ:NVCR) - Benzinga benzinga.com - September 21 at 6:57 PM
	Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business - Business Wire businesswire.com - September 21 at 10:03 AM
	Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business finance.yahoo.com - September 21 at 10:03 AM
	NovoCure Appears Poised for an Upside Breakout - RealMoney realmoney.thestreet.com - September 14 at 11:01 PM
	Novocure Earns Relative Strength Rating Upgrade - Investor's Business Daily investors.com - September 12 at 10:54 AM
	UPDATE 1-Ivory Coast sells 2023/24 cocoa contracts with positive origin differential - Yahoo Finance finance.yahoo.com - September 12 at 10:54 AM
	After losing 33% in the past year, NovoCure Limited (NASDAQ:NVCR) institutional owners must be relieved by the recent gain finance.yahoo.com - September 12 at 10:54 AM
	NovoCure Appears Poised for an Upside Breakout finance.yahoo.com - September 12 at 10:54 AM
	Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer - Yahoo Finance finance.yahoo.com - September 1 at 10:36 PM
	Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer - StreetInsider.com streetinsider.com - September 1 at 5:34 PM
	Novocure to Participate in Upcoming Investor Conferences - Yahoo Finance finance.yahoo.com - September 1 at 3:30 AM
	Novocure to Participate in Upcoming Investor Conferences - Business Wire businesswire.com - August 31 at 12:02 PM
	Novocure to Participate in Upcoming Investor Conferences finance.yahoo.com - August 31 at 12:02 PM
	Why I Own Novocure Stock (NVCR) - The Motley Fool fool.com - August 22 at 11:45 AM
	Why I Own Novocure Stock (NVCR) finance.yahoo.com - August 22 at 11:45 AM
	Rich Insights Into The Robust Metastatic Melanoma Clinical Trials Pipeline Analysis Featuring 75+ Companies DelveInsight - GlobeNewswire globenewswire.com - August 18 at 2:50 PM
	Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility - Business Wire businesswire.com - August 10 at 1:06 PM
	The Chief Medical Officer of NovoCure Limited (NASDAQ:NVCR), Ely Benaim, Just Sold 89% Of Their Holding nasdaq.com - August 8 at 1:44 PM
	NovoCure Earnings Perspective: Return On Capital Employed msn.com - August 4 at 1:34 PM
	5 Top Stocks for August - The Motley Fool fool.com - August 1 at 4:47 AM

Get NovoCure News Delivered to You Automatically

This page (NASDAQ:NVCR) was last updated on 3/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NovoCure - NVCR News Today

NVCR Media Mentions By Week

NVCR Media Sentiment

NVCR News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info